APA
Scherr M., Elder A., Battmer K., Barzan D., Bomken S., Ricke-Hoch M., Schröder A., Venturini L., Blair H. J., Vormoor J., Ottmann O., Ganser A., Pich A., Hilfiker-Kleiner D., Heidenreich O. & Eder M. (20140430). Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. : Leukemia.
Chicago
Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, Schröder A, Venturini L, Blair H J, Vormoor J, Ottmann O, Ganser A, Pich A, Hilfiker-Kleiner D, Heidenreich O and Eder M. 20140430. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. : Leukemia.
Harvard
Scherr M., Elder A., Battmer K., Barzan D., Bomken S., Ricke-Hoch M., Schröder A., Venturini L., Blair H. J., Vormoor J., Ottmann O., Ganser A., Pich A., Hilfiker-Kleiner D., Heidenreich O. and Eder M. (20140430). Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. : Leukemia.
MLA
Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, Schröder A, Venturini L, Blair H J, Vormoor J, Ottmann O, Ganser A, Pich A, Hilfiker-Kleiner D, Heidenreich O and Eder M. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. : Leukemia. 20140430.